Cytosine arabinoside in experimental combination therapy.
D000609:Aminoacridines / Q000008:administration & dosage; D000677:Amsacrine; D000818:Animals; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001085:Arabinofuranosylcytosine Triphosphate / Q000378:metabolism; D002945:Cisplatin / Q000008:administration & dosage; D003520:Cyclophosphamide / Q000008:administration & dosage; D003561:Cytarabine / Q000008:administration & dosage* / Q000378:metabolism; D004247:DNA / Q000096:biosynthesis; D004260:DNA Repair; D003630:Daunorubicin / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D004347:Drug Interactions; D004351:Drug Resistance; D006801:Humans; D007399:Interphase; D007938:Leukemia / Q000188:drug therapy; D015122:Mercaptopurine / Q000008:administration & dosage; D010766:Phosphorylation; D013866:Thioguanine / Q000008:administration & dosage; D013936:Thymidine / Q000008:administration & dosage / Q000031:analogs & derivatives; D013997:Time Factors
D000609:Aminoacridines; D000677:Amsacrine; D003561:Cytarabine; D001085:Arabinofuranosylcytosine Triphosphate; D004317:Doxorubicin; D003520:Cyclophosphamide; D004247:DNA; D015122:Mercaptopurine; D013866:Thioguanine; D002945:Cisplatin; D013936:Thymidine; D003630:Daunorubicin